top of page


FDA declines approval of Summit and Akeso's ivonescimab for EGFR-mutated lung cancer
The FDA has issued a Complete Response Letter for Summit Therapeutics' ivonescimab in EGFR-mutated lung cancer after the HARMONi trial demonstrated a progression-free survival benefit but did not establish a statistically significant overall-survival benefit.

nuaxia
1 day ago2 min read


AstraZeneca invests $2bn in Summit Therapeutics and expands ivonescimab cancer collaboration
AstraZeneca is investing $2bn in Summit Therapeutics alongside a clinical collaboration focused on combinations involving the PD-1/VEGF bispecific antibody ivonescimab.

nuaxia
Sep 302 min read
bottom of page